Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADER cardiovascular outcomes trial of liraglutide in high-risk adults with type 2 diabetes
NL-OMON34550Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular events composite. Started Feb 2011; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON34550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34550.